Overview
This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Eligibility
Inclusion Criteria:
- Informed consent must be obtained/signed prior to trial participation.
- Aged between 18 and 55 years old, both healthy males and females are eligible.
- Female participates must have a body weight of ≥ 45 kg and male participates ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg/m\^2.
Exclusion Criteria:
- History or presence of any clinically severe disorders of urinary, cardiovascular, endocrine, nervous, gastrointestinal, respiratory, hematologic, immune systems, psychiatric illnesses or metabolic abnormalities; or other conditions judged by the Investigator to confound trial outcomes, e.g., intestinal diseases (irritable bowel syndrome), urinary tract infections.
- History of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps).
- Any conditions or diseases that, in the Investigator's judgment, may affect the absorption, metabolism and/or excretion of the investigational product.
- History of drug abuse or dependence.
- Hypersensitivity to any ingredient of the study drug，or history of allergic disorders or allergic diathesis.
- Any other condition that, in the opinion of the investigator, renders the participant unsuitable to participate in the study.
